1. Introduction {#sec1-jcm-08-00247}
===============

For patients with end-stage renal disease (ESRD), hemodialysis is the most prevalent renal replacement therapy. Having optimal vascular access with sufficient diameter and flow rate is essential for adequate hemodialysis. Arteriovenous fistula is the ideal one rather than other vascular access, such as arteriovenous graft, bridging long-term tunneled or short-term non-tunneled catheter, which increases the risk of thrombosis, central stenosis, infections, multiple hospitalizations, higher medical costs, and greater morbidity and mortality \[[@B1-jcm-08-00247],[@B2-jcm-08-00247],[@B3-jcm-08-00247]\]. Consequently, maintaining functional fistulas is a serious challenge in the care of hemodialysis patients.

Researchers have attempted to identify variables associated with the maturation and survival of shunts, including anatomic locations and types of shunts, and demographic characteristics of patients, but the optimal puncture timing for shunts remains undetermined. One prospective observational study \[[@B4-jcm-08-00247]\] analyzed incident dialysis patients in 309 facilities in France, Germany, Italy, Japan, Spain, the United Kingdom, and the US. The researchers found significant differences in clinical practices among countries, including the time from fistula creation to initial cannulation. The median time for this ranged from 25 to 98 days. In this study, reduced fistula survival was associated with cannulation within 14 days of fistula creation. Another population-based cohort study in Canada found that fistula creation at least 4 months before starting hemodialysis was associated with the lowest risk of sepsis and death; lower risk was credited to reduced use of hemodialysis catheters \[[@B5-jcm-08-00247]\]. In contrast, Ng et al. \[[@B6-jcm-08-00247]\] observed that fistulas received puncture after starting hemodialysis for more than 1 month had longer primary patency. Individualized programs for shunts were suggested due to diversity of maturation time in this study.

The current National Kidney Foundation Dialysis Outcomes Quality Initiative (KDOQI) \[[@B7-jcm-08-00247]\] has endorsed the idea that the time required for fistula maturation varies among patients. The Work Group advised avoiding premature cannulating fistulas within the first month after construction; they also noted that a fistula should be placed for at least 6 months before hemodialysis begins, to allow shunt evaluation and additional time for revision if needed. \[[@B8-jcm-08-00247],[@B9-jcm-08-00247]\] Nevertheless, the Japanese Society of Dialysis Therapy advised that fistula be constructed at least 2--4 weeks before dialysis, based on working group opinions \[[@B10-jcm-08-00247]\]. In contrast, 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS) \[[@B11-jcm-08-00247]\] recommended that arteriovenous fistulas should be considered for cannulation 4--6 weeks after creation. Among these practice guidelines, the optimal maturation time to puncture fistula and improve fistula survival is not established.

Although the importance of functional shunts on the morbidity and mortality of patients with ESRD is well known, only about 20% of patients start hemodialysis with mature shunt, even in developed countries. \[[@B12-jcm-08-00247],[@B13-jcm-08-00247]\] One of the main reasons for this is that the appropriate time for shunt creation and cannulation is still undetermined. Therefore, we designed a study using the Taiwan Health and Welfare Database (National Health Insurance Research Database, NHIRD, previously) to estimate the optimal puncture time of a shunt to maintain its longevity.

2. Experimental Section {#sec2-jcm-08-00247}
=======================

2.1. Source of Data {#sec2dot1-jcm-08-00247}
-------------------

This retrospective cohort study was based on data from patients enrolled in the NHIRD for ESRD, which was provided from the Health and Welfare Data Science Center (HWDC). The National Health Insurance (NHI) system, a compulsory program in Taiwan, was initiated in 1995 and is co-funded by the Taiwanese government, employers, and beneficiaries. All residents, including foreigners, are mandated to join the NHI system if they have lived in Taiwan longer than 6 months. Thus, NHI data cover more than 99% of the population. The NHIRD consists of longitudinal medical records for all health beneficiaries in Taiwan. These records include patient characteristics, diagnoses, examinations, procedures, operations, and fees. The NHIRD databank was anonymized before being released for research use, to protect patient and physician privacy. The diagnoses in the NHIRD are coded using the format of the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM), and claims data of all interventions and treatments also correspond to relevant codes. We obtained ethical approval for our study from the Chang Gung Medical Foundation Institutional Review Board, and the study was conducted in full compliance with national ethical guidelines. All data were anonymized by the Taiwan NHI system, thus the institutional review board determined that patient consent was not required.

2.2. Study Population {#sec2dot2-jcm-08-00247}
---------------------

Using NHIRD data, we identified all patients with ESRD (ICD-9-CM code: 585) from 1 July 2008 to 30 June 2012. ESRD patients requiring maintenance long-term hemodialysis were confirmed by catastrophic illness certification profiles, which were applied by nephrologists; the status of ESRD had been documented by specialists in the NHI administration. We excluded patients younger than 20 years of age and patients who had undergone renal transplantation or peritoneal dialysis. The patients who have received arteriovenous fistulas creation were confirmed by relevant operative codes (AVF; procedure codes: 69032B, 69032C). In addition, patients were excluded who had unclear health records on shunt construction or cannulation or delayed shunt creation after initiating hemodialysis because we could not confirm the status of vascular access maturation. We followed patients until their deaths, deregistration, or the end of the study. The description of selection of study subjects is shown in [Figure 1](#jcm-08-00247-f001){ref-type="fig"}. A total of 26885 patients were enrolled and analyzed in this study. For the purpose of recognizing the most appropriate cannulation time of fistulas, we used quantile to group the subjects, and that of each group were within 16 days, between 17 and 31 days, between 32 to 97 days, and more than 98 days respectively. Further, to realize the association with fistula survivals and their waiting puncture time longer than 98 days, the subjects were regrouped by waiting puncture time as within 30 days, between 30 and 90 days, between 90 to 180 days, and more than 180 days on the basis of present guidance and clinical practicality.

2.3. Major Outcomes {#sec2dot3-jcm-08-00247}
-------------------

As shown in [Figure 2](#jcm-08-00247-f002){ref-type="fig"}, these 26885 patients were categorized by functional maturation time, which was defined as the duration from the date of operation for fistula creation to the date of the first successful shunt cannulation. If the patients had more than once operative records of shunt, we identified the first one as our investigation to minimize mistakes about further revision or two-stage fistulas. For those patients who never received long-term tunneled catheter implantation prior to initiating hemodialysis, we selected the date of the first hemodialysis as the first successful shunt cannulation. For those who had long-term tunneled catheter implantation, the catheter was usually removed immediately after the first successful puncture in Taiwan, thus, we selected the date of permanent tunneled catheter removal to indicate the first date of successful cannulation of the shunt. Moreover, to eliminate the effects of technical failure during operation, we excluded reports of shunts with primary failures, defined as shunt abandonment before its first use for hemodialysis.

The primary outcome of this study was the functional cumulative survival of a shunt, defined as a shunt with functional maturation until abandonment or until reaching a censored event, including missing medical records in the NHIRD, patient death, or end of the study period. Functional primary patency, defined as the functional maturation of a shunt until any first intervention (endovascular or surgical) to maintain or restore blood flow, was also investigated and regarded as secondary outcomes.

2.4. Covariates {#sec2dot4-jcm-08-00247}
---------------

Baseline demographic and clinical data, including age, gender, comorbidities, and medications, were defined as covariates. The comorbidities, such as hypertension (HTN), diabetes mellitus (DM), myocardial infarction (MI), congestive heart failure (CHF), peripheral vascular disease (PVD), and cerebrovascular disease (CVD), were identified by the diagnostic codes in two or more consecutive outpatient records during the 6 months prior to shunt construction. For medications, including aspirin, clopidogrel (Plavix^®^), warfarin, and statins, we included the data when the drug had been used for at least 1 month, as indicated by outpatient records, before or after shunt creation.

2.5. Statistical Analysis {#sec2dot5-jcm-08-00247}
-------------------------

Data regarding basic demographic characteristics, comorbidities, and medications were presented as a number (percent) for categorical variables and mean ± standard deviation (SD) for continuous variables. Pearson's chi-square test and analysis of variance were used to compare the differences in categorical and continuous variables, respectively. For each type of vascular accesses survival, Cox proportional hazard models and the Kaplan--Meier method were used to calculate hazard ratios (HRs) with 95% confidence intervals (CI). Analyses were conducted using SAS statistical software, version 9.4 (SAS Institute, Inc., Cary, NC, USA).

3. Results {#sec3-jcm-08-00247}
==========

3.1. Patient Characteristics {#sec3dot1-jcm-08-00247}
----------------------------

The demographic characteristics, comorbid diseases, and medication usage are listed in [Table S1](#app1-jcm-08-00247){ref-type="app"} and [Table 1](#jcm-08-00247-t001){ref-type="table"}. As shown in [Table S1](#app1-jcm-08-00247){ref-type="app"}, the mean days in each quantile are 8.7 days, 23.7 days, 60.9 days and 256.1 days; the time spans are within 16 days, between 17 and 31 days, between 32 and 97 days and more than 98 days, respectively. Patients in the group quantile 1 were more likely to be comorbid with HTN, DM, MI, CHF, and PVD, and to be treated with aspirin. Patients in the group quantile 4 were more likely to have CVD, and to use clopidogrel and warfarin. Otherwise, the current KDOQI \[[@B7-jcm-08-00247]\] suggested that a fistula should be placed for at least 6 months before hemodialysis begins. While grouping by using quantile, it was hard to evaluate the survival benefits of fistulas with waiting cannulation for longer than 98 days, between 98 and 6 months or longer. Consequently, based on present guidance and clinical practicality, the subjects were regrouped by waiting puncture time as within 30 days, between 30 and 90 days, between 90 to 180 days, and more than 180 days on the. [Table 1](#jcm-08-00247-t001){ref-type="table"} demonstrated that the functional maturation time of fistulas in most patients was within 30 days (49.6%). Patients with fistulas with functional maturation time within 30 days were more likely to be comorbid with HTN, DM, MI, CHF, and PVD, and to be treated with aspirin and statins. Patients with fistulas with functional maturation times greater than 180 days were more likely to have HTN, DM, CHF, PVD, CVD, and to use warfarin, but not MI, aspirin, or statins.

3.2. Functional Shunt Survivals {#sec3dot2-jcm-08-00247}
-------------------------------

[Figure 3](#jcm-08-00247-f003){ref-type="fig"} summarizes the patency of shunts studied. The 1-year, 3-year, and 5-year functional cumulative survival rates of the fistulas were 81.68%, 74.07%, and 69.54%. The 1-year, 3-year and 5-year functional primary patency rates were 54.20%, 36.51%, and 27.21%, respectively.

3.3. Optimal Functional Maturation Time of Shunts and Association between Covariates {#sec3dot3-jcm-08-00247}
------------------------------------------------------------------------------------

The analysis of the primary outcome, from shunt cannulation to abandonment, is shown in [Table S2](#app1-jcm-08-00247){ref-type="app"}, [Table 2](#jcm-08-00247-t002){ref-type="table"} and [Figure 3](#jcm-08-00247-f003){ref-type="fig"}. [Table S2](#app1-jcm-08-00247){ref-type="app"} illustrates that the fistulas, which were punctured 98 days later after creation, had better cumulative functional survivals (HR 0.899; 95% CI 0.82--0.985; *p* = 0.0226). Furthermore, as shown in [Table 2](#jcm-08-00247-t002){ref-type="table"} and [Figure 3](#jcm-08-00247-f003){ref-type="fig"}, the fistulas with functional maturation time between 91 and 180 days had the greatest cumulative functional survival (HR 0.883; 95% CI 0.792--0.984; *p* = 0.0237), while the cumulative functional survival of fistulas with functional maturation time more than 180 days (HR 0.957; 95% CI 0.853--1.073; *p* = 0.4515) was not better. Patients who had fistulas with poorer functional cumulative survival were significantly more likely to be older, female, to have a history of DM, CHF, and to be using warfarin. This finding indicated that the patients with a fistula, which was created at least 3 months prior to hemodialysis, have less chance of shunt abandonment.

[Table S3](#app1-jcm-08-00247){ref-type="app"}, [Table 3](#jcm-08-00247-t003){ref-type="table"} and [Figure 4](#jcm-08-00247-f004){ref-type="fig"} demonstrate the results of analysis of the fistulas from cannulation to the first intervention for maintaining adequate function. [Table S3](#app1-jcm-08-00247){ref-type="app"} displayed that the fistulas with functional maturation time within 16 days and between 17 and 31 days had poorer functional primary patency (HR 1.239; 95% CI 1.184--1.298; *p* \< 0.0001 and HR 1.202; 95% CI 1.148--1.254; *p* \< 0.0001). Similarly, as shown in [Table 3](#jcm-08-00247-t003){ref-type="table"}, functional maturation times within 30 days had significantly the worst functional primary patency (HR 1.234; 95% CI 1.184--1.285; *p* \< 0.0001). Regardless of which grouping, it was thought that fistulas should be created at least 1 month before beginning hemodialysis, to minimize any intervention to maintain or restore blood flow. Patients who have no history of HTN, but who have a history of DM, CHF, and of using aspirin, clopidogrel and warfarin, were significantly more likely to have fistulas with poorer functional primary patency.

3.4. Individualized Functional Maturation Time of Shunts {#sec3dot4-jcm-08-00247}
--------------------------------------------------------

Forest plots in [Figure 5](#jcm-08-00247-f005){ref-type="fig"} show hazard ratios in patients with different demographic characteristics. All subgroups demonstrated that fistulas with functional maturation time more than 90 days had superior functional cumulative survivals. This section may be divided by subheadings. It should provide a concise and precise description of the experimental results, their interpretation as well as the experimental conclusions that can be drawn.

4. Discussion {#sec4-jcm-08-00247}
=============

In this nationwide population-based, retrospective cohort study, we analyzed 26885 hemodialysis patients with fistulas in Taiwan during a 5-year follow-up period. Functional maturation time of shunts was highly associated with their survival. Fistulas with functional maturation times between 91 and 180 days had the greatest functional cumulative survival. Otherwise, although current popular KDOQI guidance advise that a fistula should be placed at least 6 months before hemodialysis is begun, fistulas with waiting times longer than 180 days for cannulation showed no additional benefit on their survivals in our study \[[@B7-jcm-08-00247]\]. Shunts should be constructed and cannulated at suitable timing, to minimize bridging catheters accompanying complications and for better long-term survival.

According to our results, the ideal functional maturation time for fistulas was between 91 and 180 days on the basis of their best functional cumulative survival. Corpataux et al. \[[@B14-jcm-08-00247]\] demonstrated hemodynamic changes during fistula maturation by using duplex ultrasound to evaluate 6 patients with fistulas in the lower arm. Venous luminal pressure increased initially after shunt creation and gradually returned to normal at 12 weeks, as did venous luminal dilation. Similarly, Wong et al. \[[@B15-jcm-08-00247]\] observed that venous luminal diameter enlarged and reached the plateau at 12 weeks after creation in forearm fistulas, and ultimately the fistulas were successful for hemodialysis. Some believe that it takes about 2--3 months for a vein to complete "arterialization" when an artery is anastomosed to a vein after a fistula creation \[[@B16-jcm-08-00247]\]. In our study, we confirmed the theoretical hemodynamic maturity of fistulas by evaluating clinical data, which showed fistulas with maturation for longer than 90 days is adequate for cannulation. On the other hand, recent one systemic review and meta-analysis \[[@B11-jcm-08-00247]\] reviewed over 8000 studies and included 318 studies comprising 62712 accesses. The mean maturation time for fistulas was 3.5 months in the included studies, but this analysis was limited by the definitions of maturation and patency reported. In our analysis, the functional maturation period of fistulas was certain as at least 90 days, and waiting longer than 180 days had no additional advantage on shunt survival. The mechanical and infectious complications of using bridging catheters could be minimized while fistulas cannulation occurred earlier than 180 days.

Our study showed that the 1-year, 3-year and 5-year functional cumulative survival of fistulas is 81.68%, 74.07%, and 69.54%, respectively. These survival rates are better than previous study results \[[@B11-jcm-08-00247],[@B17-jcm-08-00247],[@B18-jcm-08-00247]\]. One systemic review and meta-analysis \[[@B17-jcm-08-00247]\] analyzed fistulas with inclusion criteria by KDOQI guidance \[[@B7-jcm-08-00247]\], which suggests that fistulas be created at least 6 months prior to hemodialysis. That study observed that the 1-year functional secondary patency rate was 81%; this rate was similar to ours. The other recent meta-analysis \[[@B11-jcm-08-00247]\], which included more studies but inconsistent definitions about accesses maturation, reported the secondary patency at one year was 79%. In Japan, Hatakeyama et al. \[[@B18-jcm-08-00247]\] reported that the 3- and 5-year secondary patency rates were 53% to 59% and 44% to 54%, according to different types of 1560 fistulas. The fistulas were constructed at least 2 to 4 weeks before the initial cannulation for hemodialysis, according to current recommendations in Japan \[[@B10-jcm-08-00247]\]. As compared with previous investigations, our better survival rates in Taiwan imply that functional maturation time plays the key role in functional cumulative survival. According to our results, fistulas should be cannulated between 91 and 180 days after construction for the best functional cumulative survivals.

Among earlier assumptions is the belief that creating a shunt in a timely manner before hemodialysis allows adequate time for shunt maturation. However, creating shunts too early is not without problems. Some patients may develop the steal syndrome due to arterial ischemia in the distal limb, or high-output heart failure, both of which may require additional shunt revision \[[@B17-jcm-08-00247],[@B19-jcm-08-00247]\]. One retrospective study \[[@B20-jcm-08-00247]\] observed that early referral for preparing dialysis aggravated the short- and long-term health-related quality of life (HRQOL) and depression of patients with ESRD. Therefore, we realize that creating shunts too early or too late is not better than using ideal timing.

Compared with other reports in a systemic review and meta-analysis \[[@B14-jcm-08-00247]\] and Japanese records \[[@B17-jcm-08-00247],[@B21-jcm-08-00247],[@B22-jcm-08-00247]\], it is worth noting that functional primary patency of shunts in our study was inferior to other results, although we had superior outcomes in functional cumulative survival. This suggests that the first intervention to maintain or restore blood flow of shunts may be earlier in Taiwan than in other areas. In Taiwan, we evaluate functions of shunts according to the suggestions of KDOQI guidance \[[@B7-jcm-08-00247]\]; thus, earlier interventions to maintain or restore blood flow of shunts may be associated with more aggressive and experienced clinicians, and greater medical convenience by NHI. In another point of view, earlier interventions should be performed to support our excellent functional cumulative survival, but differences in medical costs between earlier interventions and reconstruction of a new shunts need to be clarified.

In our investigation of the association between covariates and shunt survivals, elderly patients, females, patients with DM, CHF, and those using warfarin had significantly inferior functional cumulative survival of fistulas. This finding agrees with the results of previous studies \[[@B23-jcm-08-00247],[@B24-jcm-08-00247],[@B25-jcm-08-00247],[@B26-jcm-08-00247]\]. From another perspective, patients with shunts of functional maturation time more than 180 days, are older, mostly females, with more comorbidities and more likely to use warfarin. We could speculate that old age, female gender, the presence of more comorbidities, and using warfarin could be the negative confounders to shunts maturation. Even though several factors are associated with the maturation and survivals of shunts, fistulas with functional maturation time more than 90 days had superior functional cumulative survivals in all subgroups according to our Forest plots in [Figure 5](#jcm-08-00247-f005){ref-type="fig"}.

In our retrospective analysis, we defined the maturation of fistulas according to clinical evaluation and the rule of 6s characteristics \[[@B7-jcm-08-00247]\]. Postoperative ultrasound of routine care may be a quantitative imaging study in assessing likelihood of AVF maturation and seems reasonable to guide clinicians in decision making \[[@B27-jcm-08-00247]\]. Robbin et al. \[[@B28-jcm-08-00247]\] concluded 6-week ultrasound of AVF blood flow, diameter, and depth are moderately predictive of AVF clinical maturation from the large Hemodialysis Fistula Maturation multicenter study. Subsequent research, including this assessment tool, should evaluate shunt maturity more comprehensively. In our study, it is worth noting that NIHRD covers the most medical records and population in Taiwan. The study population is confirmed by catastrophic illness certification, which minimizes mistakes of diagnostic ICD-9-CM codes and conditions of unexpected shunt cannulation due to acute kidney injury, and can represent almost all the hemodialysis patients. We establish shunts creation, any vascular intervention and shunt abandonment by corresponding operative and therapeutic codes, thus the functional maturation time and shunt survival can be evaluated accurately. Therefore, the results in our study are reliable and really a reflection of shunt condition. Otherwise, there are some limitations. First, in NIHRD, we could not analyze difference between subgroup of AVFs, such as radiocephalic or brachiocephalic shunts. Similarly, clinical parameters, such as anatomical location of shunt, blood pressure, physical status, smoking and body mass index, are not investigated. It should be mentioned that malnutrition-inflammation-atherosclerosis (MIA) syndrome is a feature of ESRD and also a major cause of vascular calcification \[[@B29-jcm-08-00247],[@B30-jcm-08-00247]\], which was correlated with shunt failure. Hypoalbuminemia \[[@B31-jcm-08-00247]\] and C-reactive protein (CRP) \[[@B32-jcm-08-00247]\] are associated with AVF thrombosis indirectly and directly. Laboratory data, especially including albumin and CRP, is necessary in further analysis. Second, the information about comorbidity and medications is only collected from the ICD-9-CM codes claiming for reimbursement, which may be misclassified.

5. Conclusions {#sec5-jcm-08-00247}
==============

In our retrospective analysis of NHIRD data, functional maturation time of shunts play a critical role on their survivals. The fistulas with functional maturation time between 91 and 180 days have excellent functional cumulative survivals. The fistulas should be cannulated at least 90 days after their creation, and waiting for longer than 180 days to puncture shows no further benefits regarding their survivals. Further prospective studies may be desired to confirm our perceptions, and the effort on increasing shunts creation before initiation of hemodialysis is also necessary censoriously.

Research Database data was provided by the Applied Health Research Data Integration Service from National Health Insurance Administration and Health and Welfare Data Science Center. The authors are thankful for the Chang Gung Memorial Hospital to offer statistical assistance and support from the Maintenance project of the Center for Big Data Analytics and Statistics.

The following are available online at <http://www.mdpi.com/2077-0383/8/2/247/s1>, Table S1: Characteristics of ESRD patients with AVF (*N* = 26885) grouped by quantile; Table S2: Hazard ratios for functional cumulative survival of AVF grouped by quantile; Table S3: Hazard ratios for functional primary patency of AVF grouped by quantile.
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jcm-08-00247-t001_Table 1

###### 

Characteristics of ESRD patients with AVF (*N* = 26885).

  Demographic Characteristics      Functional Maturation Time   *p* Value                                 
  -------------------------------- ---------------------------- ------------- ------------- ------------- ----------
  Number of populations, *n* (%)   13341 (49.6)                 6339 (23.6)   4002 (14.9)   3203 (11.9)   
  Men, *n* (%)                     8149 (61.1)                  3931 (62.0)   2228 (55.7)   1565 (48.9)   \<0.0001
  Age (year), mean ± SD            62.4 ± 13.3                  63.1 ± 13.1   64.0 ± 13.0   66.3 ± 12.5   \<0.0001
  Age group (year), *n* (%)                                                                               \<0.0001
   \<30                            188 (1.5)                    79 (1.2)      47 (1.2)      20 (0.6)      
   31--50                          2250 (18.2)                  956 (15.1)    527 (13.2)    310 (9.7)     
   51--70                          6847 (55.4)                  3315 (52.3)   2045 (51.1)   1528 (47.7)   
   \>70                            3071 (24.9)                  1989 (31.4)   1383 (34.6)   1345 (42.0)   
  Comorbidity, *n* (%)                                                                                    
   HTN                             9469 (71.0)                  4054 (64.0)   2559 (63.9)   2375 (74.2)   \<0.0001
   DM                              6637 (49.8)                  2877 (45.4)   1744 (43.6)   1532 (47.8)   \<0.0001
   MI                              438 (3.3)                    123 (1.9)     120 (3.0)     71 (2.2)      \<0.0001
   CHF                             2669 (20.0)                  1061 (16.7)   675 (16.9)    578 (18.1)    \<0.0001
   PVD                             298 (2.2)                    101 (1.6)     50 (1.3)      73 (2.3)      \<0.0001
   CVD                             1212 (9.1)                   534 (8.4)     387 (9.7)     349 (10.9)    0.0008
  Medication, *n* (%)                                                                                     
   Aspirin                         3996 (30.0)                  2003 (31.6)   1165 (29.1)   807 (25.2)    \<0.0001
   Clopidogrel                     1570 (11.8)                  745 (11.8)    468 (11.7)    405 (12.6)    0.5383
   Warfarin                        205 (1.5)                    108 (1.7)     76 (1.9)      72 (2.2)      0.0332
   Statins                         4690 (35.2)                  2134 (33.7)   1200 (30.0)   765 (23.9)    \<0.0001

Abbreviations: ESRD, end stage renal disease; AVF, arteriovenous fistula; SD, standard deviation; HTN, hypertension; DM, diabetes mellitus, MI, myocardial infarction; CHF, congestive heart failure; PVD, peripheral vascular disease; CVD, cerebrovascular disease.

jcm-08-00247-t002_Table 2

###### 

Hazard ratios for functional cumulative survival of AVF.

                               Event, *n* (%)   Crude HR (95% CI)      *p* Value   Adjusted HR (95% CI)   *p* Value
  ---------------------------- ---------------- ---------------------- ----------- ---------------------- -----------
  Functional maturation time                                                                              
  \<30 days                    4017(30.1)       2.252 (2.097--2.418)   \<0.0001    2.245 (2.090--2.411)   \<0.0001
  31--90 days                  934 (14.7)       1.000                              1.000                  
  91--180 days                 510 (12.7)       0.895 (0.804--0.997)   0.0445      0.883 (0.792--0.984)   0.0237
  \>180 days                   430 (13.4)       0.988 (0.882--1.108)   0.8400      0.957 (0.853--1.073)   0.4515
  Age                          5891 (21.9)      1.001 (0.999--1.003)   0.1810      1.002 (1.000--1.004)   0.0275
  Gender                                                                                                  
  Female                       2507 (22.8)      1.000                              1.000                  
  Male                         3384 (21.3)      0.942 (0.894--0.992)   0.0226      0.910 (0.864--0.960)   0.0005
  HTN                                                                                                     
  No                           1413 (16.8)      1.000                              1.000                  
  Yes                          4478 (24.3)      1.101 (1.037--1.170)   0.0018      0.976 (0.911--1.045)   0.4850
  DM                                                                                                      
  No                           2737 (19.4)      1.000                              1.000                  
  Yes                          3154 (24.7)      1.105 (1.050--1.164)   0.0001      1.094 (1.030--1.162)   0.0032
  MI                                                                                                      
  No                           5703 (21.8)      1.000                              1.000                  
  Yes                          188 (25.0)       1.148 (0.993--1.327)   0.0627      1.063 (0.912--1.239)   0.4346
  CHF                                                                                                     
  No                           4586 (20.9)      1.000                              1.000                  
  Yes                          1305 (26.2)      1.211 (1.139--1.288)   \<0.0001    1.150 (1.078--1.228)   \<0.0001
  PVD                                                                                                     
  No                           5757 (21.8)      1.000                              1.000                  
  Yes                          134 (25.7)       1.143 (0.963--1.356)   0.1272      1.054 (0.887--1.252)   0.5477
  CVD                                                                                                     
  No                           5287 (21.7)      1.000                              1.000                  
  Yes                          604 (24.3)       1.082 (0.994--1.177)   0.0676      1.077 (0.987--1.174)   0.0959
  Aspirin                                                                                                 
  No                           4136 (21.9)      1.000                              1.000                  
  Yes                          1755(22.0)       1.013 (0.958--1.071)   0.6501      1.000 (0.856--1.019)   0.9978
  Clopidogrel                                                                                             
  No                           5234 (22.1)      1.000                              1.000                  
  Yes                          657 (20.6)       0.965 (0.890--1.047)   0.3922      0.934 (0.856--1.019)   0.1224
  Warfarin                                                                                                
  No                           5771 (21.8)      1.000                              1.000                  
  Yes                          120 (26.0)       1.258 (1.050--1.508)   0.0127      1.285 (1.072--1.541)   0.0067
  Statins                                                                                                 
  No                           4017 (22.2)      1.000                              1.000                  
  Yes                          1874 (21.3)      0.943 (0.893--0.997)   0.0370      0.888 (0.838--0.941)   \<0.0001

The model was adjusted for age, gender, hypertension, diabetes mellitus, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, and use of aspirin, clopidogrel, warfarin, and statins. Abbreviations: AVF, arteriovenous fistula; HR, hazard ratios; CI, confidence interval; HTN, hypertension; DM, diabetes mellitus, MI, myocardial infarction; CHF, congestive heart failure; PVD, peripheral vascular disease; CVD, cerebrovascular disease.
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###### 

Hazard ratios for functional primary patency of AVF.

                               Event, *n* (%)   Crude HR (95% CI)      *p* Value   Adjusted HR (95% CI)   *p* Value
  ---------------------------- ---------------- ---------------------- ----------- ---------------------- -----------
  Functional maturation time                                                                              
  \<30 days                    7804 (58.5)      1.233 (1.183--1.285)   \<0.0001    1.234 (1.184--1.285)   \<0.0001
  31--90 days                  3202 (50.5)      1.000                              1.000                  
  91--180 days                 1974 (49.3)      1.040 (0.984--1.100)   0.1658      1.038 (0.981--1.098)   0.1943
  180 days                     1430 (44.7)      0.947 (0.890--1.008)   0.0892      0.941 (0.884--1.002)   0.0583
  Age                          14410(53.6)      1.005 (1.004--1.006)   \<0.0001    1.005 (1.004--1.006)   \<0.0001
  Gender                                                                                                  
  Female                       5938 (53.9)      1.000                              1.000                  
  Male                         8472 (53.4)      1.003 (0.970--1.036)   0.8763      0.996 (0.963--1.030)   0.8164
  HTN                                                                                                     
  No                           3563 (24.7)      1.000                              1.000                  
  Yes                          10847 (58.8)     1.031 (0.992--1.071)   0.1190      0.941 (0.901--0.983)   0.0065
  DM                                                                                                      
  No                           6663 (47.3)      1.000                              1.000                  
  Yes                          7747 (60.6)      1.148 (1.111--1.186)   \<0.0001    1.125 (1.082--1.169)   \<0.0001
  MI                                                                                                      
  No                           13950 (53.4)     1.000                              1.000                  
  Yes                          460 (61.2)       1.182 (1.077--1.297)   0.0004      1.009 (0.915--1.113)   0.8608
  CHF                                                                                                     
  No                           11385 (52.0)     1.000                              1.000                  
  Yes                          3025 (60.7)      1.152 (1.107--1.199)   \<0.0001    1.081 (1.036--1.128)   0.0003
  PVD                                                                                                     
  No                           14094 (53.5)     1.000                              1.000                  
  Yes                          316 (60.5)       1.121 (1.003--1.253)   0.0450      1.045 (0.934--1.169)   0.4381
  CVD                                                                                                     
  No                           12964 (53.1)     1.000                              1.000                  
  Yes                          1446 (58.3)      1.070 (1.014--1.130)   0.0144      1.006 (0.952--1.064)   0.8281
  Aspirin                                                                                                 
  No                           9870 (52.2)      1.000                              1.000                  
  Yes                          4540 (57.0)      1.157 (1.117--1.199)   \<0.0001    1.097 (1.057--1.139)   \<0.0001
  Clopidogrel                                                                                             
  No                           12609 (53.2)     1.000                              1.000                  
  Yes                          1801 (56.5)      1.157 (1.101--1.216)   \<0.0001    1.061 (1.006--1.119)   0.0302
  Warfarin                                                                                                
  No                           14130 (53.5)     1.000                              1.000                  
  Yes                          280 (60.7)       1.281 (1.138--1.442)   \<0.0001    1.248 (1.109--1.406)   0.0002
  Statins                                                                                                 
  No                           9536 (52.7)      1.000                              1.000                  
  Yes                          4874 (55.5)      1.055 (1.020--1.092)   0.0022      0.987 (0.952--1.024)   0.4988

The model was adjusted for age, gender, hypertension, diabetes mellitus, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, aspirin, clopidogrel, warfarin and statins. Abbreviations: AVF, arteriovenous fistula; HR, hazard ratios; CI, confidence interval; HTN, hypertension; DM, diabetes mellitus, MI, myocardial infarction; CHF, congestive heart failure; PVD, peripheral vascular disease; CVD, cerebrovascular disease.
